Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Category Archives: Patent Eligible Subject Matter
Genetic Technologies Affirms Ariosa/Myriad With An Introduction By The Sequenom Petition for Cert.
On April 1st, Lilly filed an amicus brief in favor of Sequenom’s petition for cert. seeking to reverse Ariosa, that caused a lot of buzz in the IP community. (A copy is available at the end of this post.) To … Continue reading
Bristol-Myers Squibb v. Merck – Mayo/Alice Rule Reaches Medical Treatment Methods.
In Bristol-Myers Squibb v. Merck, Civil Action No. 150572-GMS (D. Del., 2016), Bristol-Myers sued Merck for inducing infringement of U.S. Pat. No. 9,073,994. Claim 1 reads: “A method of treating a metastatic melanoma comprising intravenously administering an effective amount of … Continue reading
Posted in Patent Eligible Subject Matter
Tagged Alice, Bristol-Myers Squibb, Judge Lourie, Mayo, Merck, Patent Law, Prometheus, Supreme Court
3 Comments
Superman Breyer v. Batman Lourie Battle in the Sequenom Petition for Cert.
Since this is an amplification of my last post on the Sequenom petition for cert. in Sequenom v. Ariosa, please go back at read my first post on the petition. I have been arguing for some years that the patent … Continue reading
Sequenom Files Petition for Cert. After Invalidation of Cff Patent
Sequenom, the loser in “Ariosa,” has filed a petition seeking Supreme Court review of the Fed. Cir.’s invalidation of the claims of US Pat. No. 6,258,540 as an attempt to claim a natural product, cffDNA. While there is no dispute … Continue reading